ArticleMolecular diversity2026
Enhancing the identification of malonylation sites using AlphaFold2 and ensemble learning.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Malonylation modification of proteins is closely related to many diseases, such as diabetes and cancer. Therefore, accurate identification of malonylation modification sites is crucial for elucidating the molecular mechanisms underlying these diseases. Traditional experimental methods suffer from the problems of high cost, long cycle time, difficulty, etc. With advancements in artificial intelligence, the prediction of protein post-translational modification sites through computational methods has emerged as a vital complement to experimental approaches. In this paper, we present a malonylation site prediction model, Catsoft_Kmalsite, the core innovation of which lies in its integration of complementary information from protein three-dimensional structural features and sequence/physicochemical features, coupled with a soft voting ensemble strategy based on Bayesian-optimized base classifiers. Specifically, we utilize AlphaFold2 to acquire protein tertiary structural information and employ CTDC, EAAC, and EGAAC methods to extract protein sequence and physicochemical features. Subsequently, two base classifiers are constructed using the CatBoost algorithm based on these two distinct feature sets, respectively. Following parameter fine-tuning of the base classifiers via Bayesian optimization, they are ultimately integrated using a soft voting strategy. All ablation experimental results show that the Catsoft_Kmalsite model exhibited good robustness and generalization ability. Across six metrics, including AUC, ACC, Sen, Pre, F1, and MCC, the model achieved average performances of 94.03%, 87.91%, 89.15%, 86.91%, 88.00%, and 0.7585, respectively, in fivefold cross-validation and specific performance of 95.18%, 89.55%, 90.87%, 88.79%, 89.82%, and 0.7912 on the independent test set; Catsoft_Kmalsite also outperformed other state-of-the-art studies in all evaluated metrics. Furthermore, we have developed a website for users to use ( http://1.94.102.146:8501/Catsoft_Kmalsite ). The code and dataset of Catsoft_Kmalsite are available at https://github.com/flyinsky6/Catsoft_Kmalsite .
Indexed as
Identifiers
41046492What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.